Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and ...

Note that the Masimo trade secret lawsuit against Apple is separate from both an ITC injunction preventing the sale of Apple ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

It was really about the O2 sensor patent infringement case Masimo brought against Apple. In theory, that’s a completely unrelated case. In practice, not so much. If you need a quick recap ...

Apple convinced a federal jury on Friday that health monitoring tech company Masimo's smartwatches infringe two of its design patents. The jury, in Delaware, agreed with Apple that Masimo's W1 and ...

Masimo Corporation (NASDAQ:MASI) is a global medical technology company specializing in noninvasive patient monitoring technologies. It develops and manufactures monitoring devices, sensors ...

New features like the Tides App on the Watch Ultra 2 probably don't get as the still-missing pulse oximetry sensing. © Photo: Florence Ion / Gizmodo For most regular ...

Unrecognized Contract Revenues: $1.65 billion as of the end of Q3. Masimo Corp (NASDAQ:MASI) reported healthcare revenues of $343 million for the third quarter, representing a 12% growth compared ...